|Bid||0.00 x 900|
|Ask||136.66 x 1100|
|Day's Range||135.85 - 137.38|
|52 Week Range||90.64 - 137.38|
|Beta (3Y Monthly)||0.32|
|PE Ratio (TTM)||48.77|
|Forward Dividend & Yield||1.56 (1.15%)|
|1y Target Est||N/A|
ResMed (RMD) achieves double-digit global revenue growth in the fourth quarter, led by strong sales at Software-as-a-Service businesses as well as of new mask products and devices.
ResMed (RMD) delivered earnings and revenue surprises of 3.26% and 0.47%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Carlisle, Northrop Grumman, ResMed, T. Rowe Price and JetBlue Airways
ResMed's (RMD) new product menu and an array of strategies are likely to benefit from the sleep-disordered breathing market. This should further drive its short-term performance.
Today we are going to look at ResMed Inc. (NYSE:RMD) to see whether it might be an attractive investment prospect. In...
Measuring ResMed Inc.'s (NYSE:RMD) track record of past performance is an insightful exercise for investors. It...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
ResMed (RMD) registers double-digit global revenue growth in Q3 on the back of solid sales from Software-as-a-Service businesses and new mask products plus devices.
ResMed (RMD) delivered earnings and revenue surprises of 5.95% and -0.19%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?